Pfizer checks if Mom's shot shields newborns from dangerous RSV
NCT ID NCT07122661
Summary
This study aims to see how well a vaccine (ABRYSVO) given to pregnant women works in the real world to protect their babies from being hospitalized with severe RSV lung infections. Researchers will look at the medical records of babies under 1 year old who were hospitalized in Australia with breathing problems, comparing those who had RSV to those who did not. The main goal is to measure the vaccine's effectiveness in preventing RSV hospitalizations in infants during their first 6 months of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY TRACT DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Sydney, Australia
Conditions
Explore the condition pages connected to this study.